Abstract:Background: The difficulties and incurability of spinal muscular atrophy (SMA) highlight the importance of prenatal diagnosis in families with SMA. However, the system applied in prenatal screening is far from perfect.Objectives: To optimize the molecular assays and establish a relatively perfect system for prenatal screening.Design, Setting, and Patients: A total of 87 patients and 132 parents from 77 families with SMA were screened for SMN1 mutations. Prenatal prediction was performed for 11 fetuses from 10 families with SMA. All of the samples to be tested were from the Department of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.Main Outcome Measures: All of the 87 patients and their parents were screened for SMN1 deletion by restriction fragment length polymorphism analysis and denaturing high-performance liquid chromatography (DHPLC). For those patients without the SMN1 deletion, the SMN1 copy numbers were detected by real-time fluorescence quantitative polymerase chain reaction and the subtle mutations of SMN were screened by direct sequencing. Prenatal prediction was performed by restriction fragment length polymorphism analysis, DHPLC, and linkage analysis for 11 fetuses. Furthermore, the SMN1 copy numbers and detected carriers of SMA were found by DHPLC and real-time fluorescence quantitative polymerase chain reaction in 14 parents and the fetuses without the SMN1 deletion. Results in aborted fetuses and born babies were reconfirmed by restriction fragment length polymorphism analysis and DHPLC. The born babies were followed up and physically examined twice a year.Results: The frequency of the SMN1 deletion we detected was 93.5% (72 of 77 patients). No subtle mutations were detected in the other 5 families. Four fetuses had the SMN1 deletion and were aborted. The other 7 fetuses, 4 carriers and 3 normal individuals, were born under suggestion by the physician. Fourteen parents were carriers. The reconfirmation of results in the aborted fetuses and born babies was completely consistent with prenatal prediction. The 7 born babies were followed up until recently and all were normal.Conclusions: The molecular diagnosis system based on restriction fragment length polymorphism analysis, DHPLC, and linkage analysis is an efficient and accurate method that is well suited for routine use in clinical laboratories.

Prepotency Service for Families with High Risk of Duchenne Muscular Dystrophy and Spinal Muscular Atrophy Utilizing Defective Single - Child Identification

[Prenatal Diagnosis of Spinal Muscular Atrophy Using Multiple Ligation-Dependent Probe Amplification].

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Generation of Five Induced Pluripotent Stem Cell Lines with DMD/c.497G > T Mutation from Renal Epithelial Cells of a Duchenne Muscular Dystrophy Patient and a Recessive Carrier Parent

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Classification and Interpretation for 11 FBN1 Variants Responsible for Marfan Syndrome and Pre-implantation Genetic Testing (PGT) for Two Families Successfully Blocked Transmission of the Pathogenic Mutations

Parental Mosaicism Detection and Preimplantation Genetic Testing in Families with Multiple Transmissions of De Novo Mutations.

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

Preimplantational Genetic Diagnosis and Mutation Detection in A Family with Duplication Mutation of Dmd Gene

Molecular Analysis and Prenatal Prediction of Spinal Muscular Atrophy in Chinese Patients by the Combination of Restriction Fragment Length Polymorphism Analysis, Denaturing High-Performance Liquid Chromatography, and Linkage Analysis

[Carrier screening model for Duchenne muscular dystrophy for women of reproductive age based on a pre-pregnancy birth defect control platform].

[Mutation analysis and prenatal diagnosis of sporadic DMD/BMD families].

Prenatal Diagnosis of Werdnig-Hoffmann Disease in China.

[Analysis of Results of Prenatal Diagnosis for 67 Pedigrees Affected with Duchenne Muscular Dystrophy in the Central Plain Region of China].

Development of a Comprehensive Real-Time PCR Assay for Dystrophin Gene Analysis and Prenatal Diagnosis of Chinese Families.

Haplotype-Based Approach for Noninvasive Prenatal Tests of Duchenne Muscular Dystrophy Using Cell-Free Fetal Dna in Maternal Plasma

Optimization of short tandem repeats and their application in prenatal diagnosis of spinal muscular atrophy

Primary Study on Prenatal Diagnosis of Duchenne Muscular Dystrophy

Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing

[Genotype, Phenotype Analysis and Follow-Up Study on Patients with Duchenne/Becker Muscular Dystrophy].